nifedipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium channel blockers, nifedipine derivatives | 1922 | 21829-25-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
| 30 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.01 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.71 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.79 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 7.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.90 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 31, 1981 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Premature delivery | 442.37 | 9.70 | 298 | 55468 | 25806 | 53267494 |
| Exposure during pregnancy | 253.50 | 9.70 | 462 | 55304 | 124398 | 53168902 |
| Premature baby | 230.25 | 9.70 | 180 | 55586 | 19621 | 53273679 |
| Low birth weight baby | 159.39 | 9.70 | 93 | 55673 | 6244 | 53287056 |
| Pre-eclampsia | 151.89 | 9.70 | 101 | 55665 | 8546 | 53284754 |
| Foetal exposure during pregnancy | 128.98 | 9.70 | 170 | 55596 | 34545 | 53258755 |
| Hypertension | 115.46 | 9.70 | 504 | 55262 | 224927 | 53068373 |
| Blood pressure inadequately controlled | 105.18 | 9.70 | 65 | 55701 | 4846 | 53288454 |
| Maternal exposure during pregnancy | 90.57 | 9.70 | 362 | 55404 | 155277 | 53138023 |
| Premature labour | 89.98 | 9.70 | 86 | 55680 | 12276 | 53281024 |
| Alopecia | 84.03 | 9.70 | 73 | 55693 | 234510 | 53058790 |
| Pemphigus | 74.97 | 9.70 | 10 | 55756 | 104021 | 53189279 |
| Hypotension | 73.09 | 9.70 | 485 | 55281 | 253591 | 53039709 |
| Caesarean section | 72.48 | 9.70 | 90 | 55676 | 17230 | 53276070 |
| Renal impairment | 68.35 | 9.70 | 217 | 55549 | 83101 | 53210199 |
| Oedema peripheral | 67.83 | 9.70 | 355 | 55411 | 170432 | 53122868 |
| Blood pressure increased | 65.01 | 9.70 | 305 | 55461 | 140174 | 53153126 |
| Glossodynia | 62.72 | 9.70 | 14 | 55752 | 100277 | 53193023 |
| Foetal growth restriction | 58.16 | 9.70 | 53 | 55713 | 7121 | 53286179 |
| Rheumatoid arthritis | 55.26 | 9.70 | 158 | 55608 | 314373 | 52978927 |
| Contraindicated product administered | 53.84 | 9.70 | 38 | 55728 | 135591 | 53157709 |
| Drug ineffective | 50.37 | 9.70 | 580 | 55186 | 816665 | 52476635 |
| Blood pressure diastolic abnormal | 49.31 | 9.70 | 53 | 55713 | 8692 | 53284608 |
| Neovascularisation | 48.42 | 9.70 | 20 | 55746 | 627 | 53292673 |
| Cardiac failure congestive | 47.83 | 9.70 | 208 | 55558 | 92549 | 53200751 |
| Scleroderma | 46.13 | 9.70 | 40 | 55726 | 5035 | 53288265 |
| Pulmonary oedema | 44.11 | 9.70 | 140 | 55626 | 53583 | 53239717 |
| Primary hyperaldosteronism | 43.91 | 9.70 | 11 | 55755 | 61 | 53293239 |
| Arthropathy | 43.74 | 9.70 | 50 | 55716 | 141403 | 53151897 |
| Systemic lupus erythematosus | 43.69 | 9.70 | 40 | 55726 | 125374 | 53167926 |
| Blood pressure systolic abnormal | 43.33 | 9.70 | 45 | 55721 | 7094 | 53286206 |
| Proteinuria | 43.26 | 9.70 | 72 | 55694 | 17996 | 53275304 |
| Dyspnoea exertional | 43.05 | 9.70 | 141 | 55625 | 54859 | 53238441 |
| Intestinal angioedema | 41.96 | 9.70 | 18 | 55748 | 621 | 53292679 |
| Discomfort | 41.65 | 9.70 | 24 | 55742 | 95448 | 53197852 |
| Heart rate decreased | 40.70 | 9.70 | 107 | 55659 | 36840 | 53256460 |
| Cerebral infarction | 40.37 | 9.70 | 83 | 55683 | 24361 | 53268939 |
| Oligohydramnios | 39.97 | 9.70 | 40 | 55726 | 6036 | 53287264 |
| Acute pulmonary oedema | 39.62 | 9.70 | 46 | 55720 | 8209 | 53285091 |
| Therapeutic product effect decreased | 39.30 | 9.70 | 44 | 55722 | 125611 | 53167689 |
| Drug dispensed to wrong patient | 39.17 | 9.70 | 13 | 55753 | 216 | 53293084 |
| Pericarditis | 38.28 | 9.70 | 10 | 55756 | 64396 | 53228904 |
| Treatment failure | 37.97 | 9.70 | 47 | 55719 | 128356 | 53164944 |
| Blood aldosterone increased | 37.67 | 9.70 | 12 | 55754 | 174 | 53293126 |
| Joint swelling | 37.51 | 9.70 | 123 | 55643 | 234515 | 53058785 |
| Infusion related reaction | 37.43 | 9.70 | 66 | 55700 | 155891 | 53137409 |
| Drug abuse | 37.41 | 9.70 | 11 | 55755 | 65515 | 53227785 |
| Wound | 37.19 | 9.70 | 25 | 55741 | 91532 | 53201768 |
| Eclampsia | 36.60 | 9.70 | 14 | 55752 | 357 | 53292943 |
| Transfusion | 36.11 | 9.70 | 57 | 55709 | 13630 | 53279670 |
| Hypergammaglobulinaemia | 36.08 | 9.70 | 15 | 55751 | 478 | 53292822 |
| Rectal prolapse | 35.65 | 9.70 | 23 | 55743 | 1848 | 53291452 |
| Rash | 35.62 | 9.70 | 297 | 55469 | 445894 | 52847406 |
| Polyhydramnios | 34.35 | 9.70 | 24 | 55742 | 2201 | 53291099 |
| Neutropenia | 33.33 | 9.70 | 73 | 55693 | 159112 | 53134188 |
| Rheumatoid factor positive | 32.09 | 9.70 | 3 | 55763 | 41195 | 53252105 |
| Bladder prolapse | 31.68 | 9.70 | 22 | 55744 | 1998 | 53291302 |
| Hypersensitivity | 31.26 | 9.70 | 114 | 55652 | 210551 | 53082749 |
| Hypertensive crisis | 31.04 | 9.70 | 55 | 55711 | 14451 | 53278849 |
| Renal artery stenosis | 30.76 | 9.70 | 21 | 55745 | 1855 | 53291445 |
| Phaeochromocytoma | 30.70 | 9.70 | 14 | 55752 | 560 | 53292740 |
| Sinusitis | 30.05 | 9.70 | 84 | 55682 | 168480 | 53124820 |
| Dialysis | 30.00 | 9.70 | 45 | 55721 | 10297 | 53283003 |
| CD30 expression | 29.24 | 9.70 | 7 | 55759 | 31 | 53293269 |
| Foetal death | 29.03 | 9.70 | 42 | 55724 | 9305 | 53283995 |
| Psoriasis | 28.90 | 9.70 | 29 | 55737 | 87060 | 53206240 |
| Injection site erythema | 28.89 | 9.70 | 23 | 55743 | 77226 | 53216074 |
| Dyspnoea | 28.86 | 9.70 | 809 | 54957 | 585423 | 52707877 |
| Blood creatinine increased | 28.85 | 9.70 | 166 | 55600 | 82496 | 53210804 |
| Pain | 28.64 | 9.70 | 438 | 55328 | 587960 | 52705340 |
| Neonatal respiratory distress syndrome | 28.50 | 9.70 | 24 | 55742 | 2903 | 53290397 |
| Premature separation of placenta | 28.50 | 9.70 | 20 | 55746 | 1847 | 53291453 |
| Bradycardia | 28.36 | 9.70 | 148 | 55618 | 70908 | 53222392 |
| Blood pressure systolic increased | 28.26 | 9.70 | 91 | 55675 | 35086 | 53258214 |
| Aplastic anaemia | 28.23 | 9.70 | 39 | 55727 | 8282 | 53285018 |
| Respiratory tract inflammation | 27.39 | 9.70 | 13 | 55753 | 570 | 53292730 |
| Tubulointerstitial nephritis | 27.20 | 9.70 | 56 | 55710 | 16448 | 53276852 |
| Product complaint | 26.91 | 9.70 | 47 | 55719 | 12210 | 53281090 |
| Angina unstable | 26.84 | 9.70 | 36 | 55730 | 7432 | 53285868 |
| Renin decreased | 25.30 | 9.70 | 8 | 55758 | 113 | 53293187 |
| Pulmonary hypertension | 25.18 | 9.70 | 91 | 55675 | 37179 | 53256121 |
| Porphyria acute | 25.12 | 9.70 | 12 | 55754 | 534 | 53292766 |
| Product residue present | 24.87 | 9.70 | 26 | 55740 | 4130 | 53289170 |
| Electrocardiogram PR prolongation | 24.81 | 9.70 | 13 | 55753 | 706 | 53292594 |
| Synovitis | 24.68 | 9.70 | 47 | 55719 | 107846 | 53185454 |
| Wrist deformity | 24.61 | 9.70 | 18 | 55748 | 1773 | 53291527 |
| Oedema | 24.45 | 9.70 | 147 | 55619 | 74199 | 53219101 |
| Foetal exposure timing unspecified | 24.40 | 9.70 | 9 | 55757 | 207 | 53293093 |
| Fatigue | 24.12 | 9.70 | 581 | 55185 | 729925 | 52563375 |
| Cardiac failure | 24.08 | 9.70 | 163 | 55603 | 85681 | 53207619 |
| Foetal distress syndrome | 24.00 | 9.70 | 16 | 55750 | 1359 | 53291941 |
| Infrequent bowel movements | 23.39 | 9.70 | 15 | 55751 | 1193 | 53292107 |
| Helicobacter infection | 23.34 | 9.70 | 6 | 55760 | 39063 | 53254237 |
| Patent ductus arteriosus | 23.29 | 9.70 | 25 | 55741 | 4093 | 53289207 |
| Thermal burn | 23.20 | 9.70 | 28 | 55738 | 5205 | 53288095 |
| Anuria | 22.65 | 9.70 | 44 | 55722 | 12396 | 53280904 |
| Fluid overload | 22.36 | 9.70 | 72 | 55694 | 27759 | 53265541 |
| Peripartum cardiomyopathy | 22.23 | 9.70 | 8 | 55758 | 171 | 53293129 |
| Injection site inflammation | 22.11 | 9.70 | 22 | 55744 | 3296 | 53290004 |
| Finger amputation | 22.04 | 9.70 | 11 | 55755 | 539 | 53292761 |
| Drug ineffective for unapproved indication | 21.80 | 9.70 | 59 | 55707 | 20661 | 53272639 |
| Hepatic enzyme increased | 21.67 | 9.70 | 64 | 55702 | 126131 | 53167169 |
| BRASH syndrome | 21.56 | 9.70 | 8 | 55758 | 187 | 53293113 |
| Maternal condition affecting foetus | 21.44 | 9.70 | 8 | 55758 | 190 | 53293110 |
| Lower respiratory tract infection | 21.37 | 9.70 | 39 | 55727 | 90942 | 53202358 |
| Cerebrovascular accident | 21.27 | 9.70 | 185 | 55581 | 104989 | 53188311 |
| Blood urea increased | 21.20 | 9.70 | 68 | 55698 | 26163 | 53267137 |
| HELLP syndrome | 21.11 | 9.70 | 13 | 55753 | 963 | 53292337 |
| Pain in jaw | 20.79 | 9.70 | 91 | 55675 | 40578 | 53252722 |
| Aortic dissection | 20.78 | 9.70 | 16 | 55750 | 1704 | 53291596 |
| Injection site reaction | 20.73 | 9.70 | 14 | 55752 | 51152 | 53242148 |
| Diabetic nephropathy | 20.65 | 9.70 | 15 | 55751 | 1462 | 53291838 |
| Drug intolerance | 20.61 | 9.70 | 128 | 55638 | 205365 | 53087935 |
| Endometritis | 20.49 | 9.70 | 13 | 55753 | 1015 | 53292285 |
| Knee arthroplasty | 20.36 | 9.70 | 5 | 55761 | 33564 | 53259736 |
| Paradoxical drug reaction | 20.25 | 9.70 | 21 | 55745 | 3304 | 53289996 |
| Cognitive disorder | 19.89 | 9.70 | 11 | 55755 | 44767 | 53248533 |
| Renal hypoplasia | 19.49 | 9.70 | 5 | 55761 | 31 | 53293269 |
| Aortic valve incompetence | 19.44 | 9.70 | 28 | 55738 | 6177 | 53287123 |
| Blood pressure fluctuation | 19.39 | 9.70 | 81 | 55685 | 35389 | 53257911 |
| Bradycardia foetal | 19.11 | 9.70 | 9 | 55757 | 388 | 53292912 |
| Infection | 19.00 | 9.70 | 104 | 55662 | 172101 | 53121199 |
| Hyperkalaemia | 18.95 | 9.70 | 109 | 55657 | 54147 | 53239153 |
| Blood pressure diastolic decreased | 18.85 | 9.70 | 49 | 55717 | 16754 | 53276546 |
| Hypovolaemic shock | 18.64 | 9.70 | 26 | 55740 | 5571 | 53287729 |
| Urticaria | 18.55 | 9.70 | 76 | 55690 | 135809 | 53157491 |
| Left ventricular hypertrophy | 18.50 | 9.70 | 25 | 55741 | 5198 | 53288102 |
| Peripheral vascular disorder | 18.32 | 9.70 | 27 | 55739 | 6081 | 53287219 |
| Abdominal discomfort | 18.11 | 9.70 | 146 | 55620 | 220916 | 53072384 |
| Barotrauma | 18.10 | 9.70 | 7 | 55759 | 184 | 53293116 |
| Foetal exposure during delivery | 17.76 | 9.70 | 5 | 55761 | 46 | 53293254 |
| Vascular resistance systemic increased | 17.59 | 9.70 | 3 | 55763 | 0 | 53293300 |
| Tocolysis | 17.59 | 9.70 | 3 | 55763 | 0 | 53293300 |
| Fluid retention | 17.53 | 9.70 | 107 | 55659 | 54294 | 53239006 |
| Respiratory distress | 17.53 | 9.70 | 76 | 55690 | 33751 | 53259549 |
| Uraemic encephalopathy | 17.46 | 9.70 | 7 | 55759 | 203 | 53293097 |
| Impaired healing | 17.44 | 9.70 | 25 | 55741 | 64180 | 53229120 |
| Preterm premature rupture of membranes | 17.34 | 9.70 | 13 | 55753 | 1330 | 53291970 |
| Vitamin D decreased | 17.28 | 9.70 | 32 | 55734 | 8697 | 53284603 |
| Multiple sclerosis relapse | 17.22 | 9.70 | 13 | 55753 | 44840 | 53248460 |
| Oral herpes | 17.20 | 9.70 | 55 | 55711 | 21124 | 53272176 |
| Swelling | 17.17 | 9.70 | 123 | 55643 | 190982 | 53102318 |
| Nephrogenic systemic fibrosis | 17.16 | 9.70 | 23 | 55743 | 4744 | 53288556 |
| Atrioventricular block first degree | 16.94 | 9.70 | 27 | 55739 | 6508 | 53286792 |
| Febrile neutropenia | 16.75 | 9.70 | 55 | 55711 | 104881 | 53188419 |
| Palpitations | 16.69 | 9.70 | 172 | 55594 | 102176 | 53191124 |
| Wrong technique in product usage process | 16.68 | 9.70 | 23 | 55743 | 60009 | 53233291 |
| Hypertensive emergency | 16.53 | 9.70 | 14 | 55752 | 1707 | 53291593 |
| Injection site pruritus | 16.04 | 9.70 | 12 | 55754 | 41577 | 53251723 |
| Atrial septal defect | 15.82 | 9.70 | 27 | 55739 | 6887 | 53286413 |
| Product substitution error | 15.70 | 9.70 | 4 | 55762 | 24 | 53293276 |
| Product use issue | 15.56 | 9.70 | 84 | 55682 | 139500 | 53153800 |
| Adverse drug reaction | 15.45 | 9.70 | 20 | 55746 | 53605 | 53239695 |
| Hyperuricaemia | 15.43 | 9.70 | 23 | 55743 | 5233 | 53288067 |
| Blood pressure decreased | 15.32 | 9.70 | 114 | 55652 | 61755 | 53231545 |
| Laboratory test interference | 15.30 | 9.70 | 9 | 55757 | 613 | 53292687 |
| Myocardial infarction | 15.28 | 9.70 | 165 | 55601 | 99189 | 53194111 |
| Shock | 15.21 | 9.70 | 56 | 55710 | 23083 | 53270217 |
| Pseudolymphoma | 15.18 | 9.70 | 9 | 55757 | 622 | 53292678 |
| Suicidal ideation | 15.06 | 9.70 | 25 | 55741 | 60486 | 53232814 |
| Malignant hypertension | 14.94 | 9.70 | 11 | 55755 | 1095 | 53292205 |
| Renal failure | 14.79 | 9.70 | 189 | 55577 | 118263 | 53175037 |
| Drug titration error | 14.77 | 9.70 | 9 | 55757 | 654 | 53292646 |
| Scleroderma renal crisis | 14.66 | 9.70 | 7 | 55759 | 311 | 53292989 |
| Ileal ulcer | 14.62 | 9.70 | 8 | 55758 | 474 | 53292826 |
| Hepatic rupture | 14.59 | 9.70 | 4 | 55762 | 33 | 53293267 |
| Injection site pain | 14.50 | 9.70 | 65 | 55701 | 113326 | 53179974 |
| Foetal heart rate deceleration abnormality | 14.29 | 9.70 | 8 | 55758 | 496 | 53292804 |
| Skin induration | 14.29 | 9.70 | 17 | 55749 | 3113 | 53290187 |
| Pancreatitis haemorrhagic | 14.03 | 9.70 | 7 | 55759 | 343 | 53292957 |
| Skin hypertrophy | 13.99 | 9.70 | 17 | 55749 | 3182 | 53290118 |
| Chronic kidney disease | 13.78 | 9.70 | 85 | 55681 | 43285 | 53250015 |
| Stillbirth | 13.56 | 9.70 | 25 | 55741 | 6772 | 53286528 |
| Haemoglobin decreased | 13.49 | 9.70 | 210 | 55556 | 137097 | 53156203 |
| Hypoaesthesia teeth | 13.48 | 9.70 | 4 | 55762 | 45 | 53293255 |
| Dermatophytosis of nail | 13.33 | 9.70 | 4 | 55762 | 47 | 53293253 |
| Human chorionic gonadotropin positive | 13.33 | 9.70 | 4 | 55762 | 47 | 53293253 |
| Umbilical cord vascular disorder | 13.28 | 9.70 | 5 | 55761 | 122 | 53293178 |
| Pulmonary embolism | 13.24 | 9.70 | 68 | 55698 | 114374 | 53178926 |
| Haemoperitoneum | 13.17 | 9.70 | 15 | 55751 | 2622 | 53290678 |
| Urine output decreased | 13.14 | 9.70 | 34 | 55732 | 11589 | 53281711 |
| Microvillous inclusion disease | 12.98 | 9.70 | 3 | 55763 | 11 | 53293289 |
| Cortisol increased | 12.97 | 9.70 | 7 | 55759 | 404 | 53292896 |
| Antibody test positive | 12.94 | 9.70 | 14 | 55752 | 2312 | 53290988 |
| Neonatal hyponatraemia | 12.82 | 9.70 | 4 | 55762 | 54 | 53293246 |
| Renal atrophy | 12.71 | 9.70 | 11 | 55755 | 1381 | 53291919 |
| Hypertensive cardiomyopathy | 12.69 | 9.70 | 6 | 55760 | 261 | 53293039 |
| Blood corticotrophin decreased | 12.62 | 9.70 | 6 | 55760 | 264 | 53293036 |
| Feeling cold | 12.62 | 9.70 | 49 | 55717 | 20712 | 53272588 |
| Thrombocytopenia | 12.59 | 9.70 | 89 | 55677 | 138638 | 53154662 |
| Cervical incompetence | 12.49 | 9.70 | 8 | 55758 | 635 | 53292665 |
| Cardiomegaly | 12.48 | 9.70 | 44 | 55722 | 17756 | 53275544 |
| Hospitalisation | 12.37 | 9.70 | 121 | 55645 | 70891 | 53222409 |
| Joint range of motion decreased | 12.26 | 9.70 | 44 | 55722 | 17912 | 53275388 |
| Coronary artery disease | 12.22 | 9.70 | 68 | 55698 | 33369 | 53259931 |
| Joint contracture | 12.21 | 9.70 | 12 | 55754 | 1772 | 53291528 |
| Therapeutic product effect incomplete | 12.11 | 9.70 | 52 | 55714 | 91732 | 53201568 |
| Blood lactate dehydrogenase increased | 12.11 | 9.70 | 50 | 55716 | 21731 | 53271569 |
| Spinal cord infarction | 11.93 | 9.70 | 6 | 55760 | 299 | 53293001 |
| Jaundice neonatal | 11.88 | 9.70 | 9 | 55757 | 935 | 53292365 |
| Systemic scleroderma | 11.87 | 9.70 | 9 | 55757 | 936 | 53292364 |
| Pulmonary arterial hypertension | 11.87 | 9.70 | 58 | 55708 | 27064 | 53266236 |
| Small for dates baby | 11.86 | 9.70 | 17 | 55749 | 3735 | 53289565 |
| Ventricular hypertrophy | 11.81 | 9.70 | 17 | 55749 | 3748 | 53289552 |
| Accidental exposure to product | 11.75 | 9.70 | 5 | 55761 | 23669 | 53269631 |
| Metabolic acidosis | 11.71 | 9.70 | 80 | 55686 | 42162 | 53251138 |
| Glomerulonephritis membranoproliferative | 11.62 | 9.70 | 5 | 55761 | 174 | 53293126 |
| Angina pectoris | 11.57 | 9.70 | 60 | 55706 | 28665 | 53264635 |
| Amniotic cavity infection | 11.52 | 9.70 | 10 | 55756 | 1260 | 53292040 |
| Foetal hypokinesia | 11.52 | 9.70 | 7 | 55759 | 506 | 53292794 |
| Transient ischaemic attack | 11.34 | 9.70 | 70 | 55696 | 35655 | 53257645 |
| Hypoxia | 11.28 | 9.70 | 98 | 55668 | 55582 | 53237718 |
| Neuromuscular blockade | 11.25 | 9.70 | 6 | 55760 | 338 | 53292962 |
| Gestational hypertension | 11.20 | 9.70 | 13 | 55753 | 2320 | 53290980 |
| Intestinal pseudo-obstruction | 11.17 | 9.70 | 8 | 55758 | 763 | 53292537 |
| Acute myocardial infarction | 11.11 | 9.70 | 66 | 55700 | 33169 | 53260131 |
| Ductus arteriosus premature closure | 11.10 | 9.70 | 6 | 55760 | 347 | 53292953 |
| Device expulsion | 10.99 | 9.70 | 9 | 55757 | 29804 | 53263496 |
| Stomatitis | 10.97 | 9.70 | 59 | 55707 | 98099 | 53195201 |
| Brain natriuretic peptide increased | 10.96 | 9.70 | 19 | 55747 | 4906 | 53288394 |
| Premature rupture of membranes | 10.92 | 9.70 | 19 | 55747 | 4921 | 53288379 |
| Intentional overdose | 10.88 | 9.70 | 35 | 55731 | 67170 | 53226130 |
| Skin tightness | 10.87 | 9.70 | 17 | 55749 | 4034 | 53289266 |
| Hip arthroplasty | 10.79 | 9.70 | 8 | 55758 | 27854 | 53265446 |
| Carotid artery disease | 10.70 | 9.70 | 11 | 55755 | 1714 | 53291586 |
| Hypoperfusion | 10.56 | 9.70 | 10 | 55756 | 1410 | 53291890 |
| Hyperplasia adrenal | 10.52 | 9.70 | 3 | 55763 | 29 | 53293271 |
| Right atrial enlargement | 10.49 | 9.70 | 4 | 55762 | 101 | 53293199 |
| Depressed mood | 10.43 | 9.70 | 14 | 55752 | 36950 | 53256350 |
| Shunt stenosis | 10.43 | 9.70 | 6 | 55760 | 392 | 53292908 |
| Arrhythmia | 10.40 | 9.70 | 70 | 55696 | 36709 | 53256591 |
| Live birth | 10.37 | 9.70 | 37 | 55729 | 15022 | 53278278 |
| Respiratory failure | 10.36 | 9.70 | 155 | 55611 | 100357 | 53192943 |
| Therapy partial responder | 10.26 | 9.70 | 21 | 55745 | 6142 | 53287158 |
| Ischaemic skin ulcer | 10.26 | 9.70 | 3 | 55763 | 32 | 53293268 |
| Drug interaction | 10.25 | 9.70 | 301 | 55465 | 219028 | 53074272 |
| Fibromyalgia | 10.25 | 9.70 | 19 | 55747 | 44056 | 53249244 |
| Large intestine benign neoplasm | 10.21 | 9.70 | 4 | 55762 | 109 | 53293191 |
| Muscle spasticity | 10.17 | 9.70 | 3 | 55763 | 17835 | 53275465 |
| Congenital hypothyroidism | 10.06 | 9.70 | 5 | 55761 | 243 | 53293057 |
| Pyuria | 10.02 | 9.70 | 11 | 55755 | 1847 | 53291453 |
| Peripheral ischaemia | 9.96 | 9.70 | 18 | 55748 | 4801 | 53288499 |
| Intracardiac mass | 9.79 | 9.70 | 3 | 55763 | 38 | 53293262 |
| Haemodialysis complication | 9.73 | 9.70 | 5 | 55761 | 261 | 53293039 |
| Hepatic function abnormal | 9.71 | 9.70 | 69 | 55697 | 36830 | 53256470 |
| Mallory-Weiss syndrome | 9.71 | 9.70 | 10 | 55756 | 1561 | 53291739 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Premature baby | 160.30 | 10.31 | 149 | 37857 | 18369 | 32457151 |
| Foetal exposure during pregnancy | 120.23 | 10.31 | 191 | 37815 | 41110 | 32434410 |
| Low birth weight baby | 99.46 | 10.31 | 75 | 37931 | 6919 | 32468601 |
| Photodermatosis | 80.72 | 10.31 | 28 | 37978 | 476 | 32475044 |
| Solar lentigo | 76.46 | 10.31 | 26 | 37980 | 415 | 32475105 |
| Dysplastic naevus | 74.17 | 10.31 | 25 | 37981 | 388 | 32475132 |
| Bradycardia | 67.16 | 10.31 | 210 | 37796 | 71352 | 32404168 |
| Gingival hypertrophy | 64.57 | 10.31 | 34 | 37972 | 1665 | 32473855 |
| Hypertension | 62.61 | 10.31 | 312 | 37694 | 131438 | 32344082 |
| Foetal growth restriction | 61.47 | 10.31 | 45 | 37961 | 3967 | 32471553 |
| Off label use | 57.51 | 10.31 | 176 | 37830 | 306144 | 32169376 |
| Drug abuse | 57.21 | 10.31 | 12 | 37994 | 80231 | 32395289 |
| Cerebral infarction | 53.58 | 10.31 | 107 | 37899 | 27507 | 32448013 |
| Polydactyly | 47.55 | 10.31 | 25 | 37981 | 1220 | 32474300 |
| Hyperkalaemia | 45.81 | 10.31 | 182 | 37824 | 69568 | 32405952 |
| Bezoar | 45.44 | 10.31 | 22 | 37984 | 900 | 32474620 |
| Renal impairment | 45.21 | 10.31 | 220 | 37786 | 91752 | 32383768 |
| Drug ineffective | 41.80 | 10.31 | 270 | 37736 | 383207 | 32092313 |
| Completed suicide | 39.67 | 10.31 | 213 | 37793 | 92304 | 32383216 |
| Blood creatinine increased | 39.65 | 10.31 | 219 | 37787 | 95913 | 32379607 |
| Kidney transplant rejection | 37.80 | 10.31 | 46 | 37960 | 7709 | 32467811 |
| Cardiac failure congestive | 36.81 | 10.31 | 196 | 37810 | 84656 | 32390864 |
| Blood urea increased | 36.24 | 10.31 | 101 | 37905 | 32172 | 32443348 |
| Oesophageal obstruction | 36.01 | 10.31 | 15 | 37991 | 428 | 32475092 |
| Shock | 35.95 | 10.31 | 84 | 37922 | 24030 | 32451490 |
| Death | 31.90 | 10.31 | 290 | 37716 | 382227 | 32093293 |
| Protein urine present | 31.18 | 10.31 | 34 | 37972 | 5063 | 32470457 |
| Phospholipidosis | 30.51 | 10.31 | 8 | 37998 | 48 | 32475472 |
| Neutropenia | 28.54 | 10.31 | 79 | 37927 | 142096 | 32333424 |
| Chronic kidney disease | 27.60 | 10.31 | 106 | 37900 | 39869 | 32435651 |
| Aplasia pure red cell | 27.42 | 10.31 | 34 | 37972 | 5808 | 32469712 |
| Actinic keratosis | 27.33 | 10.31 | 28 | 37978 | 3882 | 32471638 |
| Foetal exposure timing unspecified | 25.98 | 10.31 | 10 | 37996 | 231 | 32475289 |
| Hypotonic-hyporesponsive episode | 25.74 | 10.31 | 6 | 38000 | 20 | 32475500 |
| Incision site pain | 24.95 | 10.31 | 20 | 37986 | 2017 | 32473503 |
| Malignant hypertension | 23.36 | 10.31 | 13 | 37993 | 711 | 32474809 |
| Haemodilution | 23.03 | 10.31 | 6 | 38000 | 35 | 32475485 |
| Pulmonary hypertension | 22.87 | 10.31 | 64 | 37942 | 20430 | 32455090 |
| Thrombotic cerebral infarction | 22.29 | 10.31 | 10 | 37996 | 343 | 32475177 |
| Cardiac arrest | 22.25 | 10.31 | 191 | 37815 | 96585 | 32378935 |
| Blood pressure increased | 21.71 | 10.31 | 163 | 37843 | 79191 | 32396329 |
| Atrioventricular block complete | 21.50 | 10.31 | 38 | 37968 | 8906 | 32466614 |
| Hydrops foetalis | 21.47 | 10.31 | 9 | 37997 | 261 | 32475259 |
| Hypotension | 21.38 | 10.31 | 363 | 37643 | 215747 | 32259773 |
| Proteinuria | 21.17 | 10.31 | 56 | 37950 | 17299 | 32458221 |
| Pyelocaliectasis | 20.95 | 10.31 | 15 | 37991 | 1277 | 32474243 |
| Anti-erythropoietin antibody positive | 20.75 | 10.31 | 13 | 37993 | 886 | 32474634 |
| Lymphocyte count decreased | 20.73 | 10.31 | 63 | 37943 | 21056 | 32454464 |
| Cutaneous lupus erythematosus | 20.56 | 10.31 | 12 | 37994 | 719 | 32474801 |
| Hepatic function abnormal | 19.71 | 10.31 | 104 | 37902 | 44736 | 32430784 |
| Procedural hypertension | 19.69 | 10.31 | 6 | 38000 | 66 | 32475454 |
| Blood pressure decreased | 19.47 | 10.31 | 114 | 37892 | 50966 | 32424554 |
| Fatigue | 19.41 | 10.31 | 291 | 37715 | 350410 | 32125110 |
| Oedema | 19.36 | 10.31 | 104 | 37902 | 45043 | 32430477 |
| Congenital cystic lung | 19.18 | 10.31 | 8 | 37998 | 229 | 32475291 |
| Treatment failure | 19.11 | 10.31 | 11 | 37995 | 39152 | 32436368 |
| Metabolic acidosis | 19.00 | 10.31 | 96 | 37910 | 40603 | 32434917 |
| HIV associated nephropathy | 18.59 | 10.31 | 9 | 37997 | 368 | 32475152 |
| Intestinal pseudo-obstruction | 18.04 | 10.31 | 14 | 37992 | 1347 | 32474173 |
| Renal failure | 18 | 10.31 | 238 | 37768 | 134240 | 32341280 |
| Drug dependence | 17.82 | 10.31 | 3 | 38003 | 23481 | 32452039 |
| Blindness | 17.71 | 10.31 | 44 | 37962 | 13082 | 32462438 |
| Acute kidney injury | 17.59 | 10.31 | 458 | 37548 | 293010 | 32182510 |
| Lacunar infarction | 17.35 | 10.31 | 20 | 37986 | 3166 | 32472354 |
| Mixed connective tissue disease | 17.11 | 10.31 | 5 | 38001 | 47 | 32475473 |
| Hypertensive crisis | 16.90 | 10.31 | 34 | 37972 | 8783 | 32466737 |
| Patent ductus arteriosus | 16.85 | 10.31 | 20 | 37986 | 3265 | 32472255 |
| Supernumerary nipple | 16.66 | 10.31 | 5 | 38001 | 52 | 32475468 |
| Blood pressure inadequately controlled | 16.38 | 10.31 | 18 | 37988 | 2704 | 32472816 |
| Caesarean section | 16.20 | 10.31 | 16 | 37990 | 2123 | 32473397 |
| Neonatal respiratory failure | 16.02 | 10.31 | 8 | 37998 | 350 | 32475170 |
| Myocardial infarction | 15.82 | 10.31 | 220 | 37786 | 125456 | 32350064 |
| Rickets | 15.79 | 10.31 | 5 | 38001 | 63 | 32475457 |
| Pulmonary eosinophilia | 15.58 | 10.31 | 7 | 37999 | 241 | 32475279 |
| Wrong technique in product usage process | 15.53 | 10.31 | 11 | 37995 | 35048 | 32440472 |
| Pituitary tumour recurrent | 15.44 | 10.31 | 5 | 38001 | 68 | 32475452 |
| Agitation | 15.43 | 10.31 | 27 | 37979 | 57209 | 32418311 |
| Polyhydramnios | 15.31 | 10.31 | 7 | 37999 | 251 | 32475269 |
| Sclerodactylia | 15.26 | 10.31 | 4 | 38002 | 24 | 32475496 |
| Oesophageal haemorrhage | 15.10 | 10.31 | 12 | 37994 | 1195 | 32474325 |
| Meningitis staphylococcal | 15.05 | 10.31 | 5 | 38001 | 74 | 32475446 |
| Rheumatoid arthritis | 14.97 | 10.31 | 18 | 37988 | 44526 | 32430994 |
| Naevus flammeus | 14.93 | 10.31 | 6 | 38000 | 156 | 32475364 |
| Renal ischaemia | 14.84 | 10.31 | 9 | 37997 | 579 | 32474941 |
| Congenital pulmonary valve atresia | 14.81 | 10.31 | 5 | 38001 | 78 | 32475442 |
| Red blood cells urine positive | 14.73 | 10.31 | 14 | 37992 | 1772 | 32473748 |
| Cerebrovascular accident | 14.71 | 10.31 | 160 | 37846 | 86160 | 32389360 |
| Therapeutic product effect incomplete | 14.65 | 10.31 | 16 | 37990 | 41325 | 32434195 |
| Renal failure neonatal | 14.64 | 10.31 | 5 | 38001 | 81 | 32475439 |
| Febrile neutropenia | 14.62 | 10.31 | 81 | 37925 | 119485 | 32356035 |
| Chorioretinopathy | 14.60 | 10.31 | 13 | 37993 | 1514 | 32474006 |
| Post procedural urine leak | 14.48 | 10.31 | 6 | 38000 | 169 | 32475351 |
| Pulmonary oedema | 14.36 | 10.31 | 98 | 37908 | 46169 | 32429351 |
| Cerebral hyperperfusion syndrome | 14.20 | 10.31 | 5 | 38001 | 89 | 32475431 |
| Nephrogenic systemic fibrosis | 13.86 | 10.31 | 21 | 37985 | 4331 | 32471189 |
| Myocardial ischaemia | 13.85 | 10.31 | 49 | 37957 | 17710 | 32457810 |
| Cell marker increased | 13.77 | 10.31 | 8 | 37998 | 475 | 32475045 |
| Acute lung injury | 13.71 | 10.31 | 12 | 37994 | 1366 | 32474154 |
| Aortic dissection | 13.67 | 10.31 | 16 | 37990 | 2574 | 32472946 |
| Blood pressure systolic | 13.66 | 10.31 | 3 | 38003 | 7 | 32475513 |
| Nausea | 13.63 | 10.31 | 279 | 37727 | 320570 | 32154950 |
| Exposure during pregnancy | 13.59 | 10.31 | 32 | 37974 | 9197 | 32466323 |
| Hyphaema | 13.49 | 10.31 | 8 | 37998 | 494 | 32475026 |
| Palatal swelling | 13.47 | 10.31 | 4 | 38002 | 40 | 32475480 |
| Hydrocele male infected | 13.47 | 10.31 | 4 | 38002 | 40 | 32475480 |
| Congenital hearing disorder | 13.34 | 10.31 | 5 | 38001 | 107 | 32475413 |
| Squamous cell carcinoma of skin | 13.32 | 10.31 | 33 | 37973 | 9793 | 32465727 |
| Neonatal respiratory distress syndrome | 13.20 | 10.31 | 20 | 37986 | 4127 | 32471393 |
| Prinzmetal angina | 13.15 | 10.31 | 10 | 37996 | 934 | 32474586 |
| Azotaemia | 13.14 | 10.31 | 23 | 37983 | 5351 | 32470169 |
| Cardiac cirrhosis | 13.12 | 10.31 | 4 | 38002 | 44 | 32475476 |
| Chronic allograft nephropathy | 13.11 | 10.31 | 11 | 37995 | 1182 | 32474338 |
| Bradycardia foetal | 13.10 | 10.31 | 7 | 37999 | 353 | 32475167 |
| Diabetes mellitus | 13.04 | 10.31 | 94 | 37912 | 45079 | 32430441 |
| Neutrophil count increased | 13.04 | 10.31 | 45 | 37961 | 16069 | 32459451 |
| Transplant rejection | 12.95 | 10.31 | 33 | 37973 | 9966 | 32465554 |
| Renal disorder | 12.90 | 10.31 | 61 | 37945 | 25122 | 32450398 |
| Drug interaction | 12.89 | 10.31 | 340 | 37666 | 217845 | 32257675 |
| Drug level increased | 12.85 | 10.31 | 52 | 37954 | 20028 | 32455492 |
| Anti-neutrophil cytoplasmic antibody positive vasculitis | 12.81 | 10.31 | 9 | 37997 | 744 | 32474776 |
| Infantile apnoea | 12.81 | 10.31 | 10 | 37996 | 971 | 32474549 |
| Photosensitivity reaction | 12.60 | 10.31 | 33 | 37973 | 10130 | 32465390 |
| Product residue present | 12.58 | 10.31 | 16 | 37990 | 2802 | 32472718 |
| Hepatocellular injury | 12.51 | 10.31 | 7 | 37999 | 25311 | 32450209 |
| Aplastic anaemia | 12.46 | 10.31 | 27 | 37979 | 7346 | 32468174 |
| Maternal exposure during pregnancy | 12.45 | 10.31 | 20 | 37986 | 4337 | 32471183 |
| Product use in unapproved indication | 12.42 | 10.31 | 56 | 37950 | 87148 | 32388372 |
| Neonatal respiratory distress | 12.40 | 10.31 | 8 | 37998 | 574 | 32474946 |
| Neonatal cholestasis | 12.38 | 10.31 | 4 | 38002 | 54 | 32475466 |
| Eating disorder symptom | 12.25 | 10.31 | 3 | 38003 | 13 | 32475507 |
| Brain stem infarction | 12.20 | 10.31 | 11 | 37995 | 1302 | 32474218 |
| Pemphigoid | 12.15 | 10.31 | 29 | 37977 | 8407 | 32467113 |
| Putamen haemorrhage | 12.07 | 10.31 | 6 | 38000 | 260 | 32475260 |
| Thrombocytopenia | 12.04 | 10.31 | 113 | 37893 | 148186 | 32327334 |
| Renal artery stenosis | 12.01 | 10.31 | 13 | 37993 | 1920 | 32473600 |
| Skin hypertrophy | 11.94 | 10.31 | 15 | 37991 | 2596 | 32472924 |
| Ventricular extrasystoles | 11.92 | 10.31 | 36 | 37970 | 11990 | 32463530 |
| Congenital musculoskeletal anomaly | 11.84 | 10.31 | 6 | 38000 | 271 | 32475249 |
| Haemoglobin decreased | 11.79 | 10.31 | 201 | 37805 | 119470 | 32356050 |
| Ventricular septal defect | 11.79 | 10.31 | 18 | 37988 | 3739 | 32471781 |
| Mucosal inflammation | 11.78 | 10.31 | 13 | 37993 | 33421 | 32442099 |
| Interstitial lung disease | 11.78 | 10.31 | 122 | 37884 | 64879 | 32410641 |
| Cardiac murmur | 11.77 | 10.31 | 26 | 37980 | 7165 | 32468355 |
| Oedema peripheral | 11.75 | 10.31 | 193 | 37813 | 113898 | 32361622 |
| Gastric cancer | 11.68 | 10.31 | 22 | 37984 | 5415 | 32470105 |
| Postrenal failure | 11.60 | 10.31 | 7 | 37999 | 446 | 32475074 |
| Kidney infection | 11.58 | 10.31 | 21 | 37985 | 5020 | 32470500 |
| Clonic convulsion | 11.49 | 10.31 | 8 | 37998 | 651 | 32474869 |
| Vomiting | 11.48 | 10.31 | 200 | 37806 | 235357 | 32240163 |
| Hypertensive emergency | 11.43 | 10.31 | 9 | 37997 | 884 | 32474636 |
| Maternal drugs affecting foetus | 11.37 | 10.31 | 19 | 37987 | 4258 | 32471262 |
| Angina unstable | 11.33 | 10.31 | 36 | 37970 | 12319 | 32463201 |
| Renal cyst haemorrhage | 11.33 | 10.31 | 5 | 38001 | 165 | 32475355 |
| Vertebral artery stenosis | 11.30 | 10.31 | 5 | 38001 | 166 | 32475354 |
| Tubulointerstitial nephritis | 11.20 | 10.31 | 49 | 37957 | 19528 | 32455992 |
| Hypocalcaemia | 11.20 | 10.31 | 55 | 37951 | 22999 | 32452521 |
| Apnoeic attack | 11.19 | 10.31 | 6 | 38000 | 305 | 32475215 |
| Anaemia neonatal | 10.96 | 10.31 | 6 | 38000 | 318 | 32475202 |
| Peripheral arterial occlusive disease | 10.92 | 10.31 | 22 | 37984 | 5687 | 32469833 |
| Systemic scleroderma | 10.90 | 10.31 | 6 | 38000 | 321 | 32475199 |
| White blood cell count increased | 10.73 | 10.31 | 84 | 37922 | 41318 | 32434202 |
| Diverticulum intestinal haemorrhagic | 10.67 | 10.31 | 13 | 37993 | 2181 | 32473339 |
| Delayed graft function | 10.64 | 10.31 | 12 | 37994 | 1855 | 32473665 |
| Neuropathy peripheral | 10.63 | 10.31 | 50 | 37956 | 76932 | 32398588 |
| Myocardial fibrosis | 10.62 | 10.31 | 8 | 37998 | 736 | 32474784 |
| Angina pectoris | 10.62 | 10.31 | 68 | 37938 | 31358 | 32444162 |
| Bradycardia neonatal | 10.53 | 10.31 | 9 | 37997 | 992 | 32474528 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C07FB03 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents and calcium channel blockers |
| ATC | C08CA05 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
| ATC | C08CA55 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
| ATC | C08GA01 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS CALCIUM CHANNEL BLOCKERS AND DIURETICS Calcium channel blockers and diuretics |
| FDA CS | M0006414 | Dihydropyridines |
| FDA MoA | N0000000069 | Calcium Channel Antagonists |
| FDA EPC | N0000175421 | Dihydropyridine Calcium Channel Blocker |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D015149 | Tocolytic Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| CHEBI has role | CHEBI:35620 | vasodilator |
| CHEBI has role | CHEBI:38215 | calcium channel blockers |
| CHEBI has role | CHEBI:66993 | anti-contraction drug |
| CHEBI has role | CHEBI:77746 | H. sapiens metabolites |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Prinzmetal angina | indication | 87343002 | |
| Angina pectoris | indication | 194828000 | |
| Premature labor | off-label use | 6383007 | |
| Raynaud's phenomenon | off-label use | 266261006 | |
| Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Stenosis of intestine | contraindication | 23065003 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Left heart failure | contraindication | 85232009 | |
| Cardiogenic shock | contraindication | 89138009 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pyloric obstruction | contraindication | 244815007 | |
| Peripheral edema | contraindication | 271809000 | |
| Continent ileostomy - stoma | contraindication | 311414006 | |
| Non-Q wave myocardial infarction | contraindication | 314207007 | |
| Acute coronary syndrome | contraindication | 394659003 | |
| Porphyria | contraindication | 418470004 | |
| Severe Aortic Valve Stenosis | contraindication |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.5 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | GATING INHIBITOR | IC50 | 7.70 | IUPHAR | CHEMBL | |||
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | Kd | 9.40 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.30 | WOMBAT-PK | |||||
| Cytochrome P450 3A4 | Enzyme | IC50 | 5.26 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.50 | PDSP | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.02 | DRUG MATRIX | |||||
| Adenosine receptor A1 | GPCR | Ki | 5.35 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.08 | CHEMBL | |||||
| Glutathione reductase, mitochondrial | Enzyme | Ki | 4.76 | CHEMBL | |||||
| Transthyretin | Secreted | IC50 | 5.66 | WOMBAT-PK | |||||
| Glycine receptor subunit alpha-1 | Ion channel | IC50 | 5.48 | CHEMBL | |||||
| Bile salt export pump | Transporter | IC50 | 4.51 | CHEMBL | |||||
| Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | Ki | 4.67 | WOMBAT-PK | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
| Potassium voltage-gated channel subfamily A member 1 | Ion channel | IC50 | 4.02 | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1S | Ion channel | INHIBITOR | IC50 | 6.30 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 5 | Ion channel | IC50 | 5.21 | CHEMBL | |||||
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | IC50 | 4.36 | DRUG MATRIX | |||||
| Glycine receptor subunit beta | Ion channel | ANTAGONIST | IC50 | 5.90 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 2 | Ion channel | Kd | 4.70 | WOMBAT-PK | |||||
| Myosin light chain kinase, smooth muscle | Kinase | IC50 | 5.69 | CHEMBL | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 4.73 | DRUG MATRIX | |||||
| C-C chemokine receptor type 2 | GPCR | Ki | 6.07 | DRUG MATRIX | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1F | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
| Glycine receptor subunit alpha-3 | Ion channel | ANTAGONIST | IC50 | 4.50 | IUPHAR | ||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 4.43 | CHEMBL | |||||
| Sodium/nucleoside cotransporter 1 | Transporter | Ki | 5.09 | DRUG MATRIX | |||||
| Adenosine receptor A2a | GPCR | Ki | 4.65 | CHEMBL | |||||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 4.82 | DRUG MATRIX | |||||
| Adenosine receptor A1 | GPCR | Ki | 5.54 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 5.40 | CHEMBL | |||||
| Adenosine receptor A2a | GPCR | Ki | 4.74 | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 9 | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | Ki | 8.46 | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | Ki | 8.92 | CHEMBL | |||||
| Cholinesterase | Enzyme | Ki | 5.92 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.82 | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 8.59 | CHEMBL | |||||
| Voltage-gated L-type calcium channel | Ion channel | Ki | 8.33 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.34 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily A member 7 | Ion channel | BLOCKER | IC50 | 4.90 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 1 | Ion channel | BLOCKER | IC50 | 4 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 2 | Ion channel | BLOCKER | Kd | 4.70 | IUPHAR | ||||
| Potassium channel subfamily K member 2 | Ion channel | IC50 | 5.09 | CHEMBL | |||||
| Bile salt export pump | Transporter | IC50 | 4.34 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018390 | VUID |
| N0000146717 | NUI |
| D00437 | KEGG_DRUG |
| 4018390 | VANDF |
| C0028066 | UMLSCUI |
| CHEBI:7565 | CHEBI |
| C5U | PDB_CHEM_ID |
| CHEMBL193 | ChEMBL_ID |
| DB01115 | DRUGBANK_ID |
| D009543 | MESH_DESCRIPTOR_UI |
| 4485 | PUBCHEM_CID |
| 2514 | IUPHAR_LIGAND_ID |
| 3222 | INN_ID |
| I9ZF7L6G2L | UNII |
| 7417 | RXNORM |
| 2302 | MMSL |
| 5175 | MMSL |
| d00051 | MMSL |
| 000710 | NDDF |
| 017700 | NDDF |
| 387490003 | SNOMEDCT_US |
| 85272000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Procardia XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2650 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | NDA | 20 sections |
| Procardia XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2660 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | NDA | 20 sections |
| Procardia XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-2670 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | NDA | 20 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2497 | CAPSULE, LIQUID FILLED | 10 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2530 | CAPSULE, LIQUID FILLED | 20 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7080 | TABLET, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7081 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7082 | TABLET, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 19 sections |
| NIFEDIPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-319 | CAPSULE, LIQUID FILLED | 10 mg | ORAL | ANDA | 19 sections |
| NIFEDIPINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-948 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 11 sections |
| nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-807 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 20 sections |
| nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-908 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 20 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-909 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 14 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-194 | CAPSULE | 10 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-195 | CAPSULE | 20 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-009 | TABLET, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 11 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-009 | TABLET, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 11 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-010 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 11 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-010 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 11 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-011 | TABLET, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 11 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24979-011 | TABLET, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 11 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-840 | TABLET, FILM COATED, EXTENDED RELEASE | 90 mg | ORAL | ANDA | 22 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42192-615 | CAPSULE, LIQUID FILLED | 10 mg | ORAL | ANDA | 17 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-095 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 22 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-209 | TABLET, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 25 sections |
| AfeditabCR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-782 | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 13 sections |
| AfeditabCR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-792 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 13 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-929 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 22 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-440 | CAPSULE | 10 mg | ORAL | ANDA | 19 sections |
| Nifedipine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0695 | TABLET, FILM COATED, EXTENDED RELEASE | 30 mg | ORAL | NDA authorized generic | 21 sections |